This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts
Stocks · News reference
Evommune's Skin Disorder Study Falls Short
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28
Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $30 to $29.
HC Wainwright & Co. Reiterates Neutral on Evommune
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Neutral.